Protection of dopaminergic neurons in hemiparkinsonian monkeys by flavouring ingredient glyceryl tribenzoate.
MPTP
Parkinson’s disease
glyceryl tribenzoate
inflammation
microglia
Journal
NeuroImmune pharmacology and therapeutics
ISSN: 2750-6665
Titre abrégé: NeuroImmune Pharm Ther
Pays: Germany
ID NLM: 9918418388006676
Informations de publication
Date de publication:
25 Mar 2022
25 Mar 2022
Historique:
received:
23
05
2022
accepted:
26
05
2022
entrez:
31
1
2023
pubmed:
1
2
2023
medline:
1
2
2023
Statut:
ppublish
Résumé
Parkinson's disease (PD) is the second most prevalent neurodegenerative disease and this study underlines the significance of a small molecule glyceryl tribenzoate (GTB), a FDA approved food additive, in preventing parkinsonian pathologies in MPTP-induced animal models. The study conducted in MPTP-induced mice demonstrated dose-dependent protection of nigral tyrosine hydroxylase (TH) and striatal dopamine level by GTB oral treatment and the optimum dose was found to be 50 mg/kg/d. In the next phase, the study was carried out in MPTP-injected hemiparkinsonian monkeys, which recapitulate better clinical parkinsonian syndromes. GTB inhibited MPTP-driven induction of glial inflammation, which was evidenced by reduced level of GTP-p21
Identifiants
pubmed: 36720111
doi: 10.1515/nipt-2022-0005
pii: nipt-2022-0005
pmc: PMC9212717
mid: NIHMS1815202
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7-22Subventions
Organisme : BLRD VA
ID : IK6 BX004982
Pays : United States
Organisme : NCCIH NIH HHS
ID : R01 AT010980
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS083054
Pays : United States
Organisme : NINDS NIH HHS
ID : R21 NS108025
Pays : United States
Informations de copyright
© 2022 the author(s), published by De Gruyter, Berlin/Boston.
Déclaration de conflit d'intérêts
Competing interests: Authors state no conflict of interest.
Références
J Neurosci. 2006 Apr 12;26(15):3942-50
pubmed: 16611810
J Neuroimmune Pharmacol. 2012 Jun;7(2):424-35
pubmed: 21701815
J Neuroimmune Pharmacol. 2013 Jun;8(3):739-55
pubmed: 23475543
Nat Med. 2004 Jul;10 Suppl:S58-62
pubmed: 15272270
Neurology. 2011 Mar 8;76(10):863-9
pubmed: 21368281
Proc Natl Acad Sci U S A. 1998 May 26;95(11):6469-73
pubmed: 9600990
J Neuroimmune Pharmacol. 2014 Mar;9(2):218-32
pubmed: 24122363
Neurobiol Dis. 2006 Oct;24(1):183-93
pubmed: 16901708
Neuroscience. 2015 Aug 27;302:59-73
pubmed: 25463515
J Neuroinflammation. 2005 Jun 03;2:14
pubmed: 15935098
Neural Regen Res. 2015 Jan;10(1):30-2
pubmed: 25788911
J Neurosci. 2021 Mar 10;41(10):2287-2300
pubmed: 33514677
Brain. 2008 Jul;131(Pt 7):1880-94
pubmed: 18504291
Cell Death Differ. 2019 Jan;26(2):213-228
pubmed: 29786072
Lancet Neurol. 2009 Apr;8(4):382-97
pubmed: 19296921
Exp Neurol. 2012 Oct;237(2):318-34
pubmed: 22750327
Front Neurol. 2018 Oct 15;9:860
pubmed: 30459700
J Clin Cell Immunol. 2017 Feb;8(1):
pubmed: 28367355
Curr Opin Neurol. 2002 Aug;15(4):467-76
pubmed: 12151845
Cell Mol Life Sci. 2017 Aug;74(15):2851-2874
pubmed: 28534083
J Immunol. 2017 Jun 1;198(11):4312-4326
pubmed: 28446566
Neurochem Int. 2015 Oct;89:181-90
pubmed: 26271432
FASEB J. 2006 Apr;20(6):670-82
pubmed: 16581975
Neurobiol Dis. 2019 Dec;132:104575
pubmed: 31445159
FASEB J. 1998 Jul;12(10):905-12
pubmed: 9657530
J Neurosci. 2009 Oct 28;29(43):13543-56
pubmed: 19864567
Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18754-9
pubmed: 18000063
Nat Commun. 2021 Sep 10;12(1):5382
pubmed: 34508096
Science. 2007 Apr 13;316(5822):222-34
pubmed: 17431167
Acta Neuropathol Commun. 2017 Nov 21;5(1):85
pubmed: 29162163
J Biol Chem. 2011 Oct 7;286(40):35104-18
pubmed: 21846727
J Neuroimmune Pharmacol. 2021 Sep;16(3):592-608
pubmed: 32889602
Curr Alzheimer Res. 2006 Dec;3(5):541-50
pubmed: 17168653
Neurobiol Dis. 2021 Jun;153:105318
pubmed: 33636386
Neuroscience. 2015 Aug 27;302:36-46
pubmed: 25783477
Neurology. 2010 Mar 23;74(12):995-1002
pubmed: 20308684
J Clin Med Res. 2015 Aug;7(8):613-9
pubmed: 26124907
Autophagy. 2019 Nov;15(11):1860-1881
pubmed: 30966861
Biomed Pharmacother. 1999 Apr;53(3):141-5
pubmed: 10349502
J Neuroimmune Pharmacol. 2012 Sep;7(3):544-56
pubmed: 22661311
Science. 2000 Oct 27;290(5492):767-73
pubmed: 11052933
Sci Signal. 2021 Oct 26;14(706):eabg4747
pubmed: 34699252
Mol Neurobiol. 2018 Jan;55(1):804-821
pubmed: 28062948
Eur J Neurol. 2000 May;7 Suppl 1:21-5
pubmed: 11054155
J Neurochem. 2000 May;74(5):2213-6
pubmed: 10800968
Neuroscience. 1996 May;72(2):355-63
pubmed: 8737406
J Neurosci. 2002 Mar 1;22(5):1763-71
pubmed: 11880505
J Neuroimmune Pharmacol. 2019 Sep;14(3):503-518
pubmed: 31119595
Curr Opin Investig Drugs. 2001 May;2(5):657-62
pubmed: 11569943
Exp Neurol. 2005 Feb;191 Suppl 1:S17-27
pubmed: 15629758
Nat Med. 2018 Jul;24(7):931-938
pubmed: 29892066
PLoS One. 2012;7(6):e38113
pubmed: 22723850
Neuropathology. 2007 Oct;27(5):494-506
pubmed: 18018486
Ann N Y Acad Sci. 2003 Jun;991:120-31
pubmed: 12846981
Hum Mol Genet. 2012 Jul 15;21(14):3173-92
pubmed: 22513881
Curr Opin Neurol. 2016 Aug;29(4):459-66
pubmed: 27257944
Neuroreport. 1995 Aug 21;6(12):1642-4
pubmed: 8527732
J Immunol. 2019 May 1;:
pubmed: 31043478
J Biol Chem. 2016 Jul 15;291(29):15267-81
pubmed: 27226559